Thomas Civik - 28 Jan 2026 Form 4 Insider Report for Repare Therapeutics Inc. (RPTX)

Role
Director
Signature
/s/ Steve Forte, Attorney-in-Fact
Issuer symbol
RPTX
Transactions as of
28 Jan 2026
Net transactions value
$0
Form type
4
Filing time
28 Jan 2026, 20:30:09 UTC
Previous filing
02 Apr 2025
Next filing
05 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Civik Thomas Director C/O REPARE THERAPEUTICS INC., 7171 FREDERICK-BANTING, BLDG 2, SUITE 27, ST-LAURENT, QUEBEC, CANADA /s/ Steve Forte, Attorney-in-Fact 28 Jan 2026 0001723092

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RPTX Common Shares Disposed to Issuer -7,500 -100% 0 28 Jan 2026 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Thomas Civik is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Pursuant to that certain Arrangement Agreement, dated November 14, 2025 (the "Arrangement Agreement"), by and between the Issuer and XenoTherapeutics, Inc. (the "Parent"), Xeno Acquisition Corp. (the "Purchaser"), and XOMA Royalty Corporation ("XRC"), in exchange for (i) $2.20 in cash per share, plus (ii) one non-transferable contingent value right ("CVR") per share.
F2 Pursuant to the Arrangement Agreement, the Purchaser acquired all of the issued and outstanding common shares of the Issuer for (i) $2.20 in cash per share plus (ii) one CVR per share.